Related Experiment Video

Updated: Oct 14, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

ID2 Inhibits Bladder Cancer Progression and Metastasis via PI3K/AKT Signaling Pathway

Weipu Mao1,2,3, Keyi Wang4, Si Sun2

  • 1Department of Urology, Shidong Hospital of Yangpu District, Shanghai, China.

Frontiers in Cell and Developmental Biology
|November 8, 2021
PubMed

Insights

Inhibitor of DNA-binding 2 (ID2) acts as a tumor suppressor in bladder cancer (BCa). Lower ID2 expression correlates with advanced BCa, while its restoration inhibits cancer progression and metastasis via the PI3K/AKT pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Inhibitors of DNA-binding (ID) proteins regulate cell proliferation and differentiation.
  • Dysregulation of ID proteins is implicated in various cancers.

Purpose of the Study:

  • To investigate the role of ID proteins, specifically ID2, in bladder cancer (BCa).
  • To elucidate the molecular mechanisms underlying ID2's function in BCa progression and metastasis.

Main Methods:

  • Analysis of TCGA database for ID protein expression and clinical significance.
  • Experimental validation of ID2 expression using qRT-PCR, immunohistochemistry, and western blot.
  • Functional assays (CCK-8, colony formation, migration, invasion, xenograft) to assess ID2's role in BCa cell behavior.
  • RNA sequencing to explore ID2's mechanism of action.

Main Results:

  • ID2 expression was significantly downregulated in BCa tissues.
  • High ID2 expression correlated with lower tumor grade and improved patient survival outcomes (OS, DSS, PFI).
  • ID2 knockdown promoted BCa cell proliferation, migration, invasion, and metastasis, whereas ID2 overexpression inhibited these processes.

Conclusions:

  • ID2 functions as a tumor suppressor in bladder cancer.
  • ID2 inhibits BCa progression and metastasis by modulating the PI3K/AKT signaling pathway.
  • Altered ID2 expression serves as a potential biomarker for BCa progression and metastasis.
Keywords:
ID2PI3K/AKT signaling pathwaybladder cancermetastasisprogression

More Related Videos

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.2K
Mouse Bladder Wall Injection03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K